Publications

Peer-reviewed journal articles

Goetjes E, Blankart KE. Insurance barriers and inequalities in health care access: evidence from dual practice. Health Econ Rev. 21. März 2024;14(1):23.

Schneider P, Blankart K, Brazier J, Hout B van, Devlin N. Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany. Value in Health. 2024 Mar 1;27(3):376–82.

Brand T, Goetjes E, Blankart K. To Seek Program Accreditation, Innovation, or Both?—Examining the Interdependencies in High-Reliability Health Care Organizations. Schmalenbach J Bus Res

Kurte MS, Blankart KE. Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017. The International Journal of Health Planning and Management. 2023

Blankart K, Naci H, Chandra A. Availability of New Medicines in the US and Germany From 2004 to 2018. JAMA Network Open. 2022 Aug 30;5(8):e2229231.

Birkner B, Blankart KE. The effect of biosimilar prescription targets for erythropoiesis-stimulating agents on physicians’ prescribing behaviour in Germany. Value in Health 2022 Data Availability and Provenance Statements..

Blankart KE, Felder S. Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020. Value in Health. 2022 Data Preparation and Analysis Codes.

Vadia R, Blankart K. Regional Innovation Systems of Medical Technology: REGION. 2021 Sep 27;8(2):57–81. Abstract & Supplementary Files ; EuHEa 2020 video presentation, starts at about 00:12:30 ; Expert discussion by Giovanni Fattore, starts at about 00:08:00.

Blankart KE, Stargardt T. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics. 2020;29(S1):63–82.

Blankart KE, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Manag Sci. 2020 Aug 8;23:605–18.

Blankart KE, Arndt F. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. International Journal of Environmental Research and Public Health. 2020 Jan;17(11):4113.

Winter V, Thomsen MK, Schreyögg J, Blankart K, Duminy L, Schoenenberger L, et al. Improving Service Provision - The Health Care Services’ Perspective. SMR. 2019;3(4):163–83.

Guhl D, Blankart KE, Stargardt T. Service quality and perceived customer value in community pharmacies. Health Services Management Research. 2019 Feb 1;32(1):36–48.

Fischer KE, Koch T, Kostev K, Stargardt T. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2018 Mar 1;19(2):213–22.

Hostenkamp G, Fischer KE, Borch-Johnsen K. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. Health Policy. 2016;120(12):1404–11.

Guhl D, Stargardt T, Schneider U, Fischer KE. Dispensing behaviour of pharmacies in prescription drug markets. Health Policy. 2016 Feb;120(2):190–7.

Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016 Nov 1;17(8):1027–40.

Fischer KE, Heisser T, Stargardt T. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. Health Policy. 2016 Oct;120(10):1115–22.

Fischer KE, Stargardt T. Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. Med Decis Making. 2014 Nov 1;34(8):1030–47.

Fischer KE, Rogowski WH. Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. International Journal of Environmental Research and Public Health. 2014 May 19;11(5):5403–30.

Fischer KE, Leidl R. Analysing coverage decision-making: opening Pandora’s box? Eur J Health Econ. 2014;15(9):889–906.

Fischer KE, Stollenwerk B, Rogowski WH. Link between Process and Appraisal in Coverage Decisions An Analysis with Structural Equation Modeling. Med Decis Making. 2013 Nov 1;33(8):1009–25.

Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy. 2013 Oct;112(3):187–96.

Fischer KE. Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. BMC Medical Informatics and Decision Making. 2012 Aug 2;12(1):83.

Fischer KE. A systematic review of coverage decision-making on health technologies—Evidence from the real world. Health Policy. 2012;107(2–3):218–30.

Fischer KE, Leidl R, Rogowski WH. A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. Health Policy. 2011 Aug;101(3):290–9.

Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. International Journal of Technology Assessment in Health Care. 2011;27(04):313–21.

Book chapters

Blankart K. Fallstudie 11: Der strategische Kampf: Wettbewerbsfähigkeit durch die europäische Waren- und Dienstleistungsfreiheit. In: Ritz A, Blankart CR, Jacobs CD, Lienhard A, Radulescu D, Sager F, editors. Praxisfälle Public Management: Ein multidisziplinärer Ansatz mit konzeptionellen Bausteinen. Wiesbaden: Springer Fachmedien; 2021. p. 107–18.

Blankart K. Fallstudie 12: Heilung um jeden Preis? – Die 20.000-€-Pille oder die Herausforderung der Preissetzungsstrategie im Gesundheitswesen. In: Ritz A, Blankart CR, Jacobs CD, Lienhard A, Radulescu D, Sager F, editors. Praxisfälle Public Management: Ein multidisziplinärer Ansatz mit konzeptionellen Bausteinen. Wiesbaden: Springer Fachmedien; 2021. p. 119–29.

Blankart K. Thema: Stakeholder Typologie nach Mitchell, Agle und Wood (1997) (Fallstudie 12). In: Ritz A, Blankart CR, Jacobs CD, Lienhard A, Radulescu D, Sager F, editors. Praxisfälle Public Management: Ein multidisziplinärer Ansatz mit konzeptionellen Bausteinen. Wiesbaden: Springer Fachmedien; 2021. p. 371–4.

Blankart K. Thema: Strategische Analyse und Prognose – Analyse brancheninterner Strukturen (Fallstudie 11). In: Ritz A, Blankart CR, Jacobs CD, Lienhard A, Radulescu D, Sager F, editors. Praxisfälle Public Management: Ein multidisziplinärer Ansatz mit konzeptionellen Bausteinen. Wiesbaden: Springer Fachmedien; 2021. p. 367–9.

Articles in German

Blankart, K., Felder, S., 2022. Arzneimittel: Placebo bei Engpassbekämpfung. Wirtschaftsdienst 2022, 248–248.

Kurte MS, Blankart K. Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. Gesundh ökon Qual manag. 2019 May 7;24(06):277–91.

Fischer K. Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013;19(3):67–81.